Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 401–500 of 1,004
Sohn, S.-J., Kim, S. Y., Kim, H. S., Chun, Y., Han, S. Y., Kim, S. H., & Moon, A. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.015 · Cited by 92
Velma, V., Dasari, S. R., & Tchounwou, P. B. (2016) · Biomarker Insights · doi:10.4137/bmi.s39445 · Cited by 98
A concise review on cobalt Schiff base complexes as anticancer agents
Kar, K., Ghosh, D., Kabi, B., & Chandra, A. (2022) · Polyhedron · doi:10.1016/j.poly.2022.115890 · Cited by 91
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Lugones, Y., Loren, P., & Salazar, L. A. (2022) · Biomolecules · doi:10.3390/biom12101365 · Cited by 101
Zhang, P., Zhang, Z., Zhou, X., Qiu, W., Chen, F., & Chen, W. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-224 · Cited by 88
Li, J. Z., Wood, W. H., Becker, K. G., Weeraratna, A. T., & Morin, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1210086 · Cited by 98
Ma, X., Zhang, J., Liu, S., Huang, Y., Chen, B., & Wang, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1722-9 · Cited by 89
Thomas, J. P., Lautermann, J., Liedert, B., Seiler, F., & Thomale, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022244 · Cited by 99
Qin, H., Leng, J., Zhang, C., Jantan, I., Amjad, M. W., Sher, M., Hassan, M. N. U., Hussain, M. A., & Bukhari, S. N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00276 · Cited by 89
Szenajch, J., Wcisło, G., Jeong, J., Szczylik, C. A., & Feldman, L. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.04.002 · Cited by 94
Wang, W., Zhao, M., Cui, L., Ren, Y., Zhang, J., Chen, J., Jia, L., Zhang, J., Yang, J., Chen, G., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01256-9 · Cited by 92
Lourda, M., Trougakos, I. P., & Gonos, E. S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22327 · Cited by 87
RetractedChen, H. H. W., Yan, J., Chen, W.-C., Kuo, M. T., Lai, Y.-H., Lai, W. W., Liu, H., & Su, W. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.011 · Cited by 97
Melnikov, S. V., Söll, D. G., Steitz, T. A., & Polikanov, Y. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw246 · Cited by 95
“Synthetic mRNA with the sequence 5 - GGC AAG GAG GUA AAA AUG UUC UAA-3 was obtained from Integrated DNA Technologies (Coralville, IA , USA).”
BackgroundInfluentialMilosavljevic, N., Duranton, C., Djerbi, N., Puech, P., Gounon, P., Lagadic‐Gossmann, D., Dimanche‐Boitrel, M., Rauch, C., Tauc, M., Counillon, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1253 · Cited by 99
Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity
Kim, J., Long, K. E., Tang, K. L., & Padanilam, B. J. (2012) · Kidney International · doi:10.1038/ki.2012.64 · Cited by 88
Claerhout, S., Verschooten, L., Kelst, S. V., Vos, R. D., Proby, C. M., Agostinis, P., & Garmyn, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25300 · Cited by 98
Xing, Y., Liu, Y., Liu, T., Meng, Q., Lu, H., Liu, W., Hu, J., Li, C., Cao, M., Yan, S., et al. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0254-x · Cited by 91
Platinum Complexes in Colorectal Cancer and Other Solid Tumors
Köberle, B., & Schoch, S. (2021) · Cancers · doi:10.3390/cancers13092073 · Cited by 94
“The extrinsic death receptor pathway is mediated through activation of the Fas/FasL system [94], while activation of pro-apoptotic members of the Bcl2 family is involved in the intrinsic mitochondrial pathway [82,90].”
BackgroundCisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity
Macciò, A., & Madeddu, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.813934 · Cited by 98
Mueller, L. P., Luetzkendorf, J., Mueller, T., Reichelt, K., Simon, H., & Schmoll, H. (2006) · STEM CELLS · doi:10.1634/stemcells.2006-0108 · Cited by 86
Cisplatin electrochemical biosensor
Petrlová, J., Potěšil, D., Zehnálek, J., Sures, B., Adam, V., Trnková, L., & Kizek, R. (2006) · Electrochimica Acta · doi:10.1016/j.electacta.2006.03.077 · Cited by 85
Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model
Almutairi, M. M., Alanazi, W. A., Alshammari, M. A., Alotaibi, M. R., Alhoshani, A., Al‐Rejaie, S. S., Hafez, M. M., & Al‐Shabanah, O. A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1976-9 · Cited by 96
“Cisplatin causes cell-cycle arrest leading to apoptosis [4], but the core mechanism is not only its ability to covalently bind to DNA but also to a broad range of essential RNA molecules.”
BackgroundWu, X., Shell, S. M., Yang, Z., & Zou, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3403 · Cited by 87
Encapsulation into Carbon Nanotubes and Release of Anticancer Cisplatin Drug Molecule
Méjri, A., Vardanega, D., Tangour, B., Gharbi, T., & Picaud, F. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp5102384 · Cited by 86
KRAB-ZFP Transcriptional Regulators Acting as Oncogenes and Tumor Suppressors: An Overview
Sobocińska, J., Molenda, S., Machnik, M., & Oleksiewicz, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042212 · Cited by 92
“It is a complex process that often involves multiple cellular pathways acting simultaneously [155,156].”
BackgroundGarmann, D., Warnecke, A., Kalayda, G. V., Kratz, F., & Jaehde, U. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.017 · Cited by 94
Biomarkers of response to therapy in oesophago-gastric cancer
Fareed, K. R., Kaye, P., Soomro, I. N., Ilyas, M., Martin, S. G., Parsons, S. L., & Madhusudan, S. (2008) · Gut · doi:10.1136/gut.2008.155861 · Cited by 92
Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1
Kang, T., & Leem, S.-H. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku094 · Cited by 95
Suberu, J., Romero‐Canelón, I., Sullivan, N. F., Lapkin, A. A., & Barker, G. C. (2014) · ChemMedChem · doi:10.1002/cmdc.201402285 · Cited by 93
Can Coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage?
Özcan, P., Fıçıcıoğlu, C., Kızılkale, Ö., Yeşiladalı, M., Tok, O. E., Özkan, F., & Eşrefoğlu, M. (2016) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-016-0751-z · Cited by 85
Torrens‐Mas, M., Pons, D. G., Sastre‐Serra, J., Oliver, J., & Roca, P. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25653 · Cited by 94
“CDDP forms DNA adducts and is used against a wide variety of tumors [Siddik, 2003; Kelland, 2007], while TAM inhibits the Conflicts of interest: The authors report no conflicts of interest.”
BackgroundInfluentialOvercoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro
Krieger, M. L., Eckstein, N., Schneider, V., Koch, M., Royer, H., Jaehde, U., & Bendas, G. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.12.061 · Cited by 84
Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., Seedhouse, C., Chan, S., & Madhusudan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057098 · Cited by 84
FOXM1 Modulates Cisplatin Sensitivity by Regulating EXO1 in Ovarian Cancer
Zhou, J., Wang, Y., Wang, Y., Yin, X., He, Y., Chen, L., Wang, W., Liu, T., & Di, W. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096989 · Cited by 92
“Cisplatin treatment caused intrastrand and interstrand DNA crosslinks (ICLs) formation and DSBs[33], triggering a subset of DNA repair machinery, such as nucleotide excision repair and homologous recombination pathways[34,35].”
BackgroundTrodello, C., Pepper, J., Wong, M. K. K., & Wysong, A. S. (2016) · Dermatologic Surgery · doi:10.1097/dss.0000000000000799 · Cited by 87
The Microbiology of Ruthenium Complexes
Southam, H. M., Butler, J. A., Chapman, J. A., & Poole, R. K. (2017) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2017.03.001 · Cited by 97
Mahnashi, M. H., Mahmoud, A. M., Alhazzani, K., Alanazi, A. Z., Alaseem, A. M., Algahtani, M., & El‐Wekil, M. M. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04781-6 · Cited by 83
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death
Low, H. B., Wong, Z. L., Wu, B., Kong, L. R., Png, C. W., Cho, Y.-L., Li, C., Xiao, F., Xin, X., Yang, H. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22638-7 · Cited by 88
Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics
Ferraro, M. G., Piccolo, M., Misso, G., Santamaria, R., & Irace, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050954 · Cited by 87
“This is consistent with the understanding that adducts induced by cisplatin disrupt replication and transcriptional processes, but that such biological effects do not necessarily correlate directly with cell death [21].”
BackgroundInfluentialNovel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin
Suzuki, K., Kokuryo, T., Senga, T., Yokoyama, Y., Nagino, M., & Hamaguchi, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01504.x · Cited by 85
DNA interstrand cross-link repair in Saccharomyces cerevisiae
Lehoczký, P., McHugh, P. J., & Chovanec, M. (2007) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00046.x · Cited by 83
Sprowl, J. A., van Doorn, L., Hu, S., van Gerven, L., de Bruijn, P., Li, L., Gibson, A. A., Mathijssen, R. H. J., & Sparreboom, A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.145 · Cited by 83
Role of JC Virus Agnoprotein in DNA Repair
Darbinyan, A., Siddiqui, K., Słonina, D., Darbinian, N., Amini, S., White, M., & Khalili, K. (2004) · Journal of Virology · doi:10.1128/jvi.78.16.8593-8600.2004 · Cited by 90
DNA damage response in nephrotoxic and ischemic kidney injury
Yan, M., Tang, C., Ma, Z., Huang, S., & Dong, Z. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.10.022 · Cited by 87
“DNA damage response in cisplatin-induced AKI Cisplatin is one of the most effective chemotherapeutic drugs for the treatment of various types of malignant tumors, such as those of ovary, lung, head, bladder, and many others (Cepeda et al., 2007; Siddik, 2003; Wang and Lippard, 2005).”
Antitumor drug delivery in multicellular spheroids by electropermeabilization
Gibot, L., Wasungu, L., Teissié, J., & Rols, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.021 · Cited by 90
Wang, X., Li, Y., Dai, Y., Liu, Q., Ning, S., Liu, J., Shen, Z., Zhu, D., Jiang, F., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep36796 · Cited by 84
Soltanmohammadi, F., Gharehbaba, A. M., Zangi, A. R., Adibkia, K., & Javadzadeh, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117248 · Cited by 95
Ding, B., Chang, Y., Li, C., Deng, X., Ding, J., Cheng, Z., Xing, B., Ma, P., & Lin, J. (2017) · Nanoscale · doi:10.1039/c7nr04166g · Cited by 82
Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
Moghadam, E. R., Ang, H. L., Asnaf, S. E., Zabolian, A., Saleki, H., Yavari, M. D., Esmaeili, H., Zarrabi, A., Ashrafizadeh, M., & Kumar, A. P. (2020) · Biomolecules · doi:10.3390/biom10101374 · Cited by 91
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Bagatell, R., Beliakoff, J., David, C. L., Marron, M. T., & Whitesell, L. J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20611 · Cited by 87
Yoon, H., Min, J., Lee, J. W., Kim, D., & Hong, H. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.130 · Cited by 81
Fareed, K. R., Al‐Attar, A., Soomro, I. N., Kaye, P., Patel, J., Lobo, D. N., Parsons, S. L., & Madhusudan, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605686 · Cited by 82
Chow, M. J., Licona, C., Pastorin, G., Mellitzer, G., Ang, W. H., & Gaiddon, C. (2016) · Chemical Science · doi:10.1039/c6sc00268d · Cited by 83
MacDonagh, L., Gallagher, M. F., Ffrench, B., Gasch, C., Breen, E. P., Gray, S. G., Nicholson, S. A., Leonard, N. A., Ryan, R. J., Young, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19881 · Cited by 87
Doucette, K. K., Hassell, K. N., & Crans, D. C. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.09.013 · Cited by 89
Agnello, L., Tortorella, S., d’Argenio, A., Carbone, C., Camorani, S., Locatelli, E., Auletta, L., Sorrentino, D., Fedele, M., Zannetti, A., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02039-w · Cited by 84
An overview of resistance to chemotherapy in osteosarcoma and future perspectives
García-Ortega, D. Y., Cabrera-Nieto, S. A., Caro-Sánchez, C. H. S., & Cruz‐Ramos, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.18 · Cited by 100
Germain, C. S., Niknejad, N., Ma, L., Garbuio, K., Hai, T., & Dimitroulakos, J. (2010) · Neoplasia · doi:10.1593/neo.92048 · Cited by 81
Gosepath, E. M., Eckstein, N., Hamacher, A., Servan, K., von Jonquières, G., Lage, H., Győrffy, B., Royer, H. D., & Kassack, M. U. (2008) · International Journal of Cancer · doi:10.1002/ijc.23721 · Cited by 85
Mirmohammadsadegh, A., Mota, R., Gustrau, A., Hassan, M., Nambiar, S., Marini, A., Bojar, H., Tannapfel, A., & Hengge, U. R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700870 · Cited by 80
Katagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 80
McCormick, M. C., Keijzer, K., Polavarapu, A., Schultz, F. A., & Baik, M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5029765 · Cited by 82
PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
Flores, O., Santra, S., Kaittanis, C., Bassiouni, R., Khaled, A. S., Khaled, A. R., Grimm, J., & Perez, J. M. (2017) · Theranostics · doi:10.7150/thno.18879 · Cited by 80
“Current cancer chemotherapeutics, such as doxorubicin and cisplatin, although highly effective, often affect not only cancer cells but also normal tissues inducing problematic sites effects.[47-49] In addition, cancer cells often develop resistance to these drugs rendering them ineffective.”
BackgroundPillozzi, S., D’Amico, M., Bartoli, G., Gasparoli, L., Petroni, G., Crociani, O., Marzo, T., Guerriero, A., Messori, L., Severi, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.392 · Cited by 93
“Overall, we believe that the results discussed herein may be of relevance for overcoming chemoresistance to Pt-based drugs, one of the major challenges in cancer treatment (Kartalou and Essigmann, 2001; Siddik, 2003; Wang and Lippard, 2005).”
BackgroundWu, F., Huang, Y., Dong, F., & Kwon, J. H. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000691 · Cited by 80
Tak, E., Lee, S., Lee, J., Rashid, M., Kim, Y. W., Park, J.-H., Park, W. S., Shokat, K. M., Ha, J., & Kim, S. S. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.045 · Cited by 84
Sirichanchuen, B., Pengsuparp, T., & Chanvorachote, P. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1199-1 · Cited by 83
γ-H2AX as a biomarker for DNA double-strand breaks in ecotoxicology
Gerić, M., Gajski, G., & Garaj‐Vrhovac, V. (2014) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2014.03.035 · Cited by 86
“Its main mode of action represents DNA crosslinking mainly due to interactions with nucleophilic N7-sites of purine bases thus leading to primarily DNA intrastrand cross-links, but also to interstrand and DNA-protein cross-links (Siddik, 2003).”
BackgroundRajalakshmi, S., Weyhermüller, T., Dinesh, M. G., & Nair, B. U. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.08.010 · Cited by 79
Peroxiredoxin 6 Overexpression Attenuates Cisplatin-Induced Apoptosis in Human Ovarian Cancer Cells
Pak, J. H., Choi, W., Lee, H. M., Joo, W.-D., Kim, J.-H., Kim, Y., Kim, Y., & Nam, J. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.535056 · Cited by 85
Chen, H., Song, I., Hossain, A., Choi, M., YAMANE, Y., Zheng, L., Lu, J., Wu, L. Y. H., Siddik, Z. H., Klomp, L. W. J., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047969 · Cited by 80
Self-citationFu, Y., Habtemariam, A., Basri, A. M., Braddick, D., Clarkson, G. J., & Sadler, P. J. (2011) · Dalton Transactions · doi:10.1039/c1dt10937e · Cited by 87
The genetic vulnerability to cisplatin ototoxicity: a systematic review
Tserga, E., Nandwani, T., Edvall, N. K., Bulla, J., Patel, P. M., Canlon, B., Cederroth, C. R., & Baguley, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-40138-z · Cited by 78
Dou, Y. N., Zheng, J., Foltz, W. D., Weersink, R., Chaudary, N., Jaffray, D. A., & Allen, C. J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.01.009 · Cited by 78
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 82
“It is well characterized that, in response to DNA damage, ATR phosphorylates and activates CHK1 which, in turn, blocks cell cycle progression and allows for proper DNA repair mechanisms to operate (Nghiem et al, 2001; Siddik, 2003).”
BackgroundInfluentialThe latest advances of cisplatin liposomal formulations: essentials for preparation and analysis
Zahednezhad, F., Zakeri‐Milani, P., Mojarrad, J. S., & Valizadeh, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1737672 · Cited by 82
Chiral Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity
Fisher, D. M., Bednarski, P. J., Grünert, R., Turner, P., Fenton, R. R., & Aldrich-Wright, J. R. (2007) · ChemMedChem · doi:10.1002/cmdc.200600211 · Cited by 78
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 77
Bradley, P. M., Angeles-Boza, A. M., Dunbar, K. R., & Turró, C. (2004) · Inorganic Chemistry · doi:10.1021/ic035424j · Cited by 78
Zhang, Z., Liu, S., Qi, Y., Zhou, D., Xie, Z., Jing, X., Chen, X., & Huang, Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.046 · Cited by 78
Sheridan, C., Brumatti, G., Elgendy, M., Brunet, M., & Martin, S. J. (2010) · Oncogene · doi:10.1038/onc.2010.380 · Cited by 71
Pénzváltó, Z., Lánczky, A., Lénárt, J., Meggyesházi, N., Krenács, T., Szoboszlai, N., Denkert, C., Pete, I., & Győrffy, B. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-837 · Cited by 88
“Platinum agents bind DNA forming inter- and intrastrand DNA adducts [6].”
BackgroundAntitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.004 · Cited by 79
Recent Developments in Texaphyrin Chemistry and Drug Discovery
Preihs, C., Arambula, J. F., Magda, D. J., Jeong, H., Yoo, D., Cheon, J., Siddik, Z. H., & Sessler, J. L. (2013) · Inorganic Chemistry · doi:10.1021/ic400226g · Cited by 88
Self-citationLu, W., Fu, Z., Wang, H., Feng, J., Wei, J., & Guo, J. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1891-4 · Cited by 81
“Cisplatin causes DNA damage and triggers the generation of ROS, which subsequently leads to cell death [6, 7].”
BackgroundAlterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)
Wang, Q., Zhong, M., Liu, W., Li, J., Huang, J., & ZHENG, L. (2011) · Experimental Lung Research · doi:10.3109/01902148.2011.584263 · Cited by 84
Gumulec, J., Balvan, J., Sztalmachová, M., Raudenská, M., Dvořáková, V., Knopfová, L., Polanska, H. H., Hudcová, K., Ruttkay-Nedecký, B., Babula, P., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2223 · Cited by 80
Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53
Sprowl, J. A., Lancaster, C. S., Pabla, N., Hermann, E., Kosloske, A. M., Gibson, A. A., Li, L., Zeeh, D., Schlatter, E., Janke, L. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0319 · Cited by 83
“The identification of the p53 pathway as a regulator of cisplatin-induced nephrotoxicity was not unanticipated, considering that p53 is the central mediator of DNA damage response which can be triggered by cisplatin (25).”
Cisplatin Mimics ARF Tumor Suppressor Regulation of RelA (p65) Nuclear Factor-κB Transactivation
Campbell, K. J., Witty, J. M., Rocha, S., & Perkins, N. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2234 · Cited by 77
Januchowski, R., Zawierucha, P., Ruciński, M., Andrzejewska, M., Wojtowicz, K., Nowicki, M. O., & Zabel, M. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.02.002 · Cited by 76
A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells
Eskandari, A., Kundu, A., Ghosh, S., & Suntharalingam, K. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905389 · Cited by 79
Vakili, M. R., Mohammed‐Saeid, W., Aljasser, A. A., Hopwood-Raja, J., Ahvazi, B. C., Hrynets, Y., Betti, M., & Lavasanifar, A. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117332 · Cited by 78
Standard methods for pollen research
Campos, M. G., Anjos, O., Chica, M., Campoy, P., Nôžková, J., Almaráz-Abarca, N., Barreto, L. M. R. C., Nordi, J. C., Estevinho, L. M., Pascoal, A., et al. (2021) · Journal of Apicultural Research · doi:10.1080/00218839.2021.1948240 · Cited by 96
Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy
Tanabe, K., Tamura, Y., Lanaspa, M. A., Miyazaki, M., Suzuki, N., Sato, W., Maeshima, Y., Schreiner, G. F., Villarreal, F. J., Johnson, R. J., et al. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00227.2012 · Cited by 77
DNA Metalating–Intercalating Hybrid Agents for the Treatment of Chemoresistant Cancers
Suryadi, J., & Bierbach, U. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201202050 · Cited by 77
Klotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3k/Akt Pathway
Wang, Y., Chen, L., Huang, G., He, D., He, J., Xu, W. D., Zou, C., Zong, F., Li, Y., Chen, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057391 · Cited by 79
Leung, E. L., Fraser, M. E., Fiscus, R. R., & Tsang, B. K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604375 · Cited by 80
Ueda, K., Kawashima, H., Ohtani, S., Deng, W., Ravoori, M. K., Bankson, J. A., Gao, B., Girard, L., Minna, J. D., Roth, J. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1483 · Cited by 76
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.